4-(aminomethyl)-N-benzylbenzamide | 18364-87-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(aminomethyl)-N-benzylbenzamide
• CAS: 18364-87-9
• 化学式: C₁₅H₁₆N₂O
• mdl: MFCD09809913
• 分子量: 240.305
• InChiKey: UTRFMKCWPPXWTE-UHFFFAOYSA-N

物化性质

• 沸点：
  464.6±38.0 °C(Predicted)
• 密度：
  1.141±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  9-[5-S-(2-acetamidoethyl)-2,3-di-O-acetyl-5-thio-β-D-ribofuranosyl]-6-fluoropurine 、 4-(aminomethyl)-N-benzylbenzamide 在 三乙胺 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Improved Syntheses of 5′-S-(2-Aminoethyl)-6-N-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), Analogues, and Fluorescent Probe Conjugates: Analysis of Cell-Surface Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels for Prediction of the Antitumor Efficacy of Gemcitabine

  摘要：

  5'-S-(2-Aminoethyl)-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAENTA), 5'-S-(2-acetamidoethyl)-6-N-[(4-substituted)benzyl]-5'-thioadenosine analogues, 5'-S-[2-(6-aminohexanamido)lethyl-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAHENTA), and related compounds were synthesized by S(N)Ar displacement of fluoride from 6-fluoropurine intermediates with 4-(substituted)benzylamines. Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. Transporter binding effects were studied and the ability of the probes to predict the potential antitumor efficacy of 2'-deoxy-2',2'-difluorocylidine (gemcitabine) was demonstrated.

  DOI：

  10.1021/jm100432w
• 作为产物：
  描述：

  N-benzyl-4-[(trifluoroacetamido)methyl]benzamide 在 ammonium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 8.0h， 生成 4-(aminomethyl)-N-benzylbenzamide
  参考文献：
  名称：

  Improved Syntheses of 5′-S-(2-Aminoethyl)-6-N-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), Analogues, and Fluorescent Probe Conjugates: Analysis of Cell-Surface Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels for Prediction of the Antitumor Efficacy of Gemcitabine

  摘要：

  5'-S-(2-Aminoethyl)-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAENTA), 5'-S-(2-acetamidoethyl)-6-N-[(4-substituted)benzyl]-5'-thioadenosine analogues, 5'-S-[2-(6-aminohexanamido)lethyl-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAHENTA), and related compounds were synthesized by S(N)Ar displacement of fluoride from 6-fluoropurine intermediates with 4-(substituted)benzylamines. Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. Transporter binding effects were studied and the ability of the probes to predict the potential antitumor efficacy of 2'-deoxy-2',2'-difluorocylidine (gemcitabine) was demonstrated.

  DOI：

  10.1021/jm100432w

文献信息

• [DE] NEUE 2-BENZYLAMINODIHYDROPTERIDINONE, VERFAHREN ZU DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] NOVEL 2-BENZYLAMINODIHYDROPTERIDINONES, METHOD FOR PRODUCING THEM AND USE THEREOF AS DRUGS<br/>[FR] NOUVEAUX 2-BENZYLAMINODIHYDROPTERIDINONES, PROCEDE DE PRODUCTION ASSOCIE ET LEUR UTILISATION EN TANT QUE MEDICAMENTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2005123736A1

  公开（公告）日：2005-12-29

  Die vorliegende Erfindung betrifft neue 2-Benzylaminodihydropteridinone der allgemeinen Formel (I) wobei die Reste R1 bis R7, R10 und R11 die in den Ansprüchen und der Beschreibung genannten Bedeutungen haben, deren Isomere, Verfahren zur Herstellung dieser Dihydropteridinone sowie deren Verwendung als Arzneimittel.

  这项发明涉及新的一般式(I)的2-苄基氨基二氢喋啉酮，其中残基R1至R7、R10和R11具有权利要求和说明中提到的含义，其异构体，制备这些二氢喋啉酮的方法以及它们作为药物的用途。
• 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
  申请人：Allen John Gordon

  公开号：US20090099155A1

  公开（公告）日：2009-04-16

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R 6 is -C≡C-R 10 , -O-R 12 , -S-R 14 , or -NR 24 R 25 ; and other substituents are as defined in the specification.

  本发明提供了式I的6-取代的2,3,4,5-四氢-1H-苯并氮烯作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为-C≡C-R10，-O-R12，-S-R14或-NR24R25；其他取代基如规范中所定义。
• 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist
  申请人：ALLEN JOHN GORDON

  公开号：US20120028961A1

  公开（公告）日：2012-02-02

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R 6 is —S—R 14 ; and other substituents are as defined in the specification.

  本发明提供了公式I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为—S—R14；其他取代基如规范中所定义。
• Site‐Specific Deaminative Trifluoromethylation of Aliphatic Primary Amines**
  作者：Jiang‐Hao Xue、Yin Li、Yuan Liu、Qingjiang Li、Honggen Wang

  DOI：10.1002/anie.202319030

  日期：2024.2.19

  A direct deaminative trifluoromethylation of inactivated aliphatic primary amines with N-anomeric amide (Levin's reagent) and bench-stable bpyCu(CF3)3 (Grushin's reagent, bpy=2,2′-bipyridine) under blue light irradiation is reported. The protocol features mild reaction conditions, good functional group tolerance and can be applied to the direct, late-stage trifluoromethylation of natural products and

  据报道，在蓝光照射下，失活的脂肪伯胺与N-异头酰胺（Levin's 试剂）和实验室稳定的 bpyCu(CF 3 ) 3 （Grushin 试剂，bpy=2,2'-联吡啶）直接脱氨三氟甲基化。该方案反应条件温和，官能团耐受性好，可应用于天然产物和生物活性分子的直接后期三氟甲基化。
• 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP2479168A1

  公开（公告）日：2012-07-25

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is -S-L-R15 and other substituents are as defined in the specification.

  本发明提供了式 I 的 6-取代 2,3,4,5-四氢-1H-苯并[d]氮杂卓作为选择性 5-HT2C 受体激动剂，用于治疗与 5-HT2C 相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症： 其中 R6 是-S-L-R15 和其他取代基如说明书中所定义。